Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 0.93 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.93 |
| ▸ | MUSK | O15146 | 1/20 | 0.93 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.93 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.93 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.93 |
| ▸ | PAK3 | O75914 | 1/20 | 0.93 |
| ▸ | STK10 | O94804 | 1/20 | 0.93 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.93 |
| ▸ | ABL1 | P00519 | 1/20 | 0.93 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.93 |
| ▸ | LCK | P06239 | 1/20 | 0.93 |
| ▸ | CSF1R | P07333 | 1/20 | 0.93 |
| ▸ | YES1 | P07947 | 1/20 | 0.93 |
| ▸ | LYN | P07948 | 1/20 | 0.93 |
| ▸ | RET | P07949 | 1/20 | 0.93 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.93 |
| ▸ | KIT | P10721 | 1/20 | 0.93 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3453696 | 0.99 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL72923 | 0.97 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL29349937 | 0.97 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL74121 | 0.96 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL29435035 | 0.96 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL742377 | 0.96 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL73566 | 0.94 | FLT3 (0.90) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL74305 | 0.94 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL72924 | 0.92 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL742748 | 0.91 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | claimed |
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2015-05-07 | — | — | US | claimed |
| US-8557810-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-15 | — | — | US | claimed |
| EP-2001892-B1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AMBIT BIOSCIENCES CORP (US) | 2013-04-24 | — | — | EP | claimed |
| US-20120129850-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2012-05-24 | — | — | US | claimed |
| US-8129374-B2 | Method of using imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCE CORPORATION (US) | 2012-03-06 | — | — | US | claimed |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2010-11-25 | — | — | US | claimed |
| US-7820657-B2 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION (US) | 2010-10-26 | — | — | US | claimed |
| EP-2001892-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | Ambit Biosciences Corporation (US) | 2008-12-17 | — | — | EP | claimed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | claimed |
| WO-2007109120-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2007-09-27 | — | — | WO | claimed |
| EP-2410987-B1 | METHODS OF TREATMENT USING COMBINATION THERAPY | AMBIT BIOSCIENCES CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921546-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20100292177-A1 | Methods of treatment using combination therapy | AMBIT BIOSCIENCES CORP. | 2010-11-18 | — | — | US | disclosed |
| US-7820657-B2 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2001892-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | Ambit Biosciences Corporation (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007109120-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | FLT3 210/4885KDR 540/4885BMPR1B 2351/4885 |
| US-20120129850-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | FLT3 210/4885KDR 540/4885BMPR1B 2351/4885 |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK5 | FLT3 363/4885KDR 675/4885BMPR1B 2817/4885 |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | FLT3 210/4885KDR 540/4885BMPR1B 2351/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | FLT3 128/4885KDR 279/4885BMPR1B 2105/4885 |
| US-20100292177-A1 | Methods of treatment using combination therapy | TOP2A, TOP2B, TOP1 | FLT3 3634/4885KDR 4201/4885BMPR1B 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.